Can primary packaging selection help mitigate particulate risks in cell and gene therapy manufacturing?

Cell & Gene Therapy Insights 2024; 10(5), 565–570

DOI: 10.18609/cgti.2024.068

Published: 4 June
Innovator Insight
Sean Werner, Joshua Jendusa, Stuart Curbishley

Primary containers are critical components of cell and gene therapy manufacturing that are a known source of particulates. This article will discuss primary container criteria that may help mitigate the risk of visible particulates within cell processing and evaluate closed-system containers as alternatives to standard cryobags.